Danthasinghe Waduge Badrajee Piyarathna1, Thekkelnaycke M Rajendiran2, Vasanta Putluri3, Venkatrao Vantaku1, Tanu Soni4, Friedrich-Carl von Rundstedt5, Sri Ramya Donepudi3, Feng Jin3, Suman Maity3, Chandrashekar R Ambati3, Jianrong Dong1, Daniel Gödde6, Stephan Roth7, Stephan Störkel6, Stephan Degener7, George Michailidis8, Seth P Lerner9, Subramaniam Pennathur10, Yair Lotan11, Cristian Coarfa12, Arun Sreekumar13, Nagireddy Putluri14. 1. Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA. 2. Department of Pathology, Michigan Regional Comprehensive Metabolomics Resource Core, Ann Arbor, Michigan, USA; Division of Bioinformatics, Michigan Regional Comprehensive Metabolomics Resource Core, Ann Arbor, Michigan, USA. 3. Dan L. Duncan Cancer Center, Advanced Technology Core, Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA. 4. Division of Bioinformatics, Michigan Regional Comprehensive Metabolomics Resource Core, Ann Arbor, Michigan, USA. 5. Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA; Department of Urology, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany. 6. Department of Pathology, Witten-Herdecke University, Wuppertal, Germany. 7. Department of Urology Helios Klinikum, Witten-Herdecke University, Wuppertal, Germany. 8. Department of Statistics, University of Florida, Gainesville, FL, USA. 9. Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA. 10. Division of Nephrology, Department of Medicine, University of Michigan, Ann Arbor MI 48015. 11. Department of Urology, University of Texas Southwestern, Dallas, TX, USA. 12. Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA; Dan L. Duncan Cancer Center, Advanced Technology Core, Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA. 13. Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA; Dan L. Duncan Cancer Center, Advanced Technology Core, Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA; Verna and Marrs McLean Department of Biochemistry, Baylor College of Medicine, Houston, TX, USA. 14. Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA; Dan L. Duncan Cancer Center, Advanced Technology Core, Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA. Electronic address: putluri@bcm.edu.
Abstract
BACKGROUND: The first global lipidomic profiles associated with urothelial cancer of the bladder (UCB) and its clinical stages associated with progression were identified. OBJECTIVE: To identify lipidomic signatures associated with survival and different clinical stages of UCB. DESIGN, SETTING, AND PARTICIPANTS: Pathologically confirmed 165 bladder-derived tissues (126 UCB, 39 benign adjacent or normal bladder tissues). UCB tissues included Ta (n=16), T1 (n=30), T2 (n=43), T3 (n=27), and T4 (n=9); lymphovascular invasion (LVI) positive (n=52) and negative (n=69); and lymph node status N0 (n=28), N1 (n=11), N2 (n=9), N3 (n=3), and Nx (n=75). RESULTS AND LIMITATIONS: UCB tissues have higher levels of phospholipids and fatty acids, and reduced levels of triglycerides compared with benign tissues. A total of 59 genes associated with altered lipids in UCB strongly correlate with patient survival in an UCB public dataset. Within UCB, there was a progressive decrease in the levels of phosphatidylserine (PS), phosphatidylethanolamines (PEs), and phosphocholines, whereas an increase in the levels of diacylglycerols (DGs) with tumor stage. Transcript and protein expression of phosphatidylserine synthase 1, which converts DGs to PSs, decreased progressively with tumor stage. Levels of DGs and lyso-PEs were significantly elevated in tumors with LVI and lymph node involvement, respectively. Lack of carcinoma in situ and treatment information is the limitation of our study. CONCLUSIONS: To date, this is the first study describing the global lipidomic profiles associated with UCB and identifies lipids associated with tumor stages, LVI, and lymph node status. Our data suggest that triglycerides serve as the primary energy source in UCB, while phospholipid alterations could affect membrane structure and/or signaling associated with tumor progression. PATIENT SUMMARY: Lipidomic alterations identified in this study set the stage for characterization of pathways associated with these altered lipids that, in turn, could inform the development of first-of-its-kind lipid-based noninvasive biomarkers and novel therapeutic targets for aggressive urothelial cancer of the bladder.
BACKGROUND: The first global lipidomic profiles associated with urothelial cancer of the bladder (UCB) and its clinical stages associated with progression were identified. OBJECTIVE: To identify lipidomic signatures associated with survival and different clinical stages of UCB. DESIGN, SETTING, AND PARTICIPANTS: Pathologically confirmed 165 bladder-derived tissues (126 UCB, 39 benign adjacent or normal bladder tissues). UCB tissues included Ta (n=16), T1 (n=30), T2 (n=43), T3 (n=27), and T4 (n=9); lymphovascular invasion (LVI) positive (n=52) and negative (n=69); and lymph node status N0 (n=28), N1 (n=11), N2 (n=9), N3 (n=3), and Nx (n=75). RESULTS AND LIMITATIONS: UCB tissues have higher levels of phospholipids and fatty acids, and reduced levels of triglycerides compared with benign tissues. A total of 59 genes associated with altered lipids in UCB strongly correlate with patient survival in an UCB public dataset. Within UCB, there was a progressive decrease in the levels of phosphatidylserine (PS), phosphatidylethanolamines (PEs), and phosphocholines, whereas an increase in the levels of diacylglycerols (DGs) with tumor stage. Transcript and protein expression of phosphatidylserine synthase 1, which converts DGs to PSs, decreased progressively with tumor stage. Levels of DGs and lyso-PEs were significantly elevated in tumors with LVI and lymph node involvement, respectively. Lack of carcinoma in situ and treatment information is the limitation of our study. CONCLUSIONS: To date, this is the first study describing the global lipidomic profiles associated with UCB and identifies lipids associated with tumor stages, LVI, and lymph node status. Our data suggest that triglycerides serve as the primary energy source in UCB, while phospholipid alterations could affect membrane structure and/or signaling associated with tumor progression. PATIENT SUMMARY:Lipidomic alterations identified in this study set the stage for characterization of pathways associated with these altered lipids that, in turn, could inform the development of first-of-its-kind lipid-based noninvasive biomarkers and novel therapeutic targets for aggressive urothelial cancer of the bladder.
Authors: Mika Hilvo; Carsten Denkert; Laura Lehtinen; Berit Müller; Scarlet Brockmöller; Tuulikki Seppänen-Laakso; Jan Budczies; Elmar Bucher; Laxman Yetukuri; Sandra Castillo; Emilia Berg; Heli Nygren; Marko Sysi-Aho; Julian L Griffin; Oliver Fiehn; Sibylle Loibl; Christiane Richter-Ehrenstein; Cornelia Radke; Tuulia Hyötyläinen; Olli Kallioniemi; Kristiina Iljin; Matej Oresic Journal: Cancer Res Date: 2011-03-17 Impact factor: 12.701
Authors: Xianlin Han; Jingyue Yang; Kui Yang; Zhongdan Zhao; Dana R Abendschein; Richard W Gross Journal: Biochemistry Date: 2007-05-08 Impact factor: 3.162
Authors: Matthew C Madison; Cameron T Landers; Bon-Hee Gu; Cheng-Yen Chang; Hui-Ying Tung; Ran You; Monica J Hong; Nima Baghaei; Li-Zhen Song; Paul Porter; Nagireddy Putluri; Ramiro Salas; Brian E Gilbert; Ilya Levental; Matthew J Campen; David B Corry; Farrah Kheradmand Journal: J Clin Invest Date: 2019-10-01 Impact factor: 14.808
Authors: Michael D Kornberg; Pavan Bhargava; Paul M Kim; Vasanta Putluri; Adele M Snowman; Nagireddy Putluri; Peter A Calabresi; Solomon H Snyder Journal: Science Date: 2018-03-29 Impact factor: 47.728
Authors: Brittany A Stork; Adam Dean; Andrea R Ortiz; Pradip Saha; Nagireddy Putluri; Maricarmen D Planas-Silva; Iqbal Mahmud; Kimal Rajapakshe; Cristian Coarfa; Stefan Knapp; Philip L Lorenzi; Bruce E Kemp; Benjamin E Turk; John W Scott; Anthony R Means; Brian York Journal: Mol Metab Date: 2022-05-11 Impact factor: 8.568